

# WFS1 P724L — Wolframin

Proline → Leucine at position 724 in luminal domain. ClinVar Conflicting. AlphaMissense 0.906,  $\Delta\Delta G$  -0.24. Same position as P724S (Atlas card adjacent) — proline-removal pair.

## IDENTITY

Variant	P724L (p.Proline724Leucine)
DNA change	c.2171C>T
Gene · Protein	WFS1 · Wolframin (890 aa)
UniProt	O76024 · WFS1_HUMAN
ClinVar accession	VCV000004509
Amino acid change	Proline (P) → Leucine (L) — rigid helix-breaking replaced by branched aliphatic. Removes backbone constraint.

## STRUCTURAL CONTEXT

AlphaFold model	AF-O76024-F1, v6
pLDDT at residue 724	<b>89.25</b> HIGH CONFIDENCE
Domain	C-terminal luminal domain (653-869)
Position context	C-terminal luminal domain · position 724 (pLDDT 89). Same as P724S.
IDR flag	No — pLDDT well above 50 threshold

Position 724 same neighbors as P724S: LEU723 (2.5 Å — partner of L723P), PHE725 (2.5 Å), PHE726 (4.6 Å), ILE727 (5.0 Å). P724L is the second substitution at 724 (with P724S). Where P724S added polarity into hydrophobic environment, P724L is conservative hydrophobic-to-hydrophobic. Both lose the backbone kink. Combined with L723P, three Atlas variants converge on the 723-724 Leu-Pro motif.  $|\Delta\Delta G|$  0.24 + AlphaMissense 0.906 confirm severe consequence.

## COMPUTATIONAL PREDICTIONS

ALPHAMISSENSE

**0.906**DYNAMUT2  $\Delta\Delta G$ 

PLDDT (ALPHAFOLD)

**89.25**

am\_class: **LPath** —  
threshold > 0.564

**-0.24** kcal/

high confidence

mol

Destabilising · Job  
177992458146

## CLINICAL EVIDENCE

ClinVar classification

### CONFLICTING CLASSIFICATIONS OF PATHOGENICITY

Review status

criteria provided, conflicting classifications

Last evaluated

2024/11/05 00:00

Inheritance

Not specified.

WFS1 variant landscape

P724L is 1 of ~326 pathogenic-spectrum  
variants in WFS1 (out of 2,243 in ClinVar)

- (no specific conditions catalogued)

## RESEARCH PATH DECISION TREE

$\Delta\Delta G < 2$  + binding site affected → CATEGORY 3 – docking experiments  $\Delta\Delta G$   
2–4 → CATEGORY 2 – pharmacological chaperones  $\Delta\Delta G > 4$  → CATEGORY 1 –  
gene therapy pLDDT < 50 → CATEGORY 5 – IDR, experimental only Stable  
fold + functional site hit → CATEGORY 4 – site-specific docking

**Category 3/4 — Most Druggable.**  $|\Delta\Delta G| = 0.24$  — fold survives.  
AlphaMissense 0.906 confirms severe consequence.

Mechanism: loss of wild-type Leu-Pro backbone geometry. Therapeutic: same  
target as L723P, P724S.

P724L + P724S + L723P all converge on the 723-724 backbone microregion  
— three convergent variant targets.